- Home
- BCG vs EGRX Comparison
BCG vs EGRX Comparison
Compare BCG & EGRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- EGRX
- Stock Information
- Founded
- BCG 2016
- EGRX 2007
- Country
- BCG United States
- EGRX United States
- Employees
- BCG N/A
- EGRX N/A
- Industry
- BCG
- EGRX Biotechnology: Pharmaceutical Preparations
- Sector
- BCG
- EGRX Health Care
- Exchange
- BCG Nasdaq
- EGRX Nasdaq
- Market Cap
- BCG 54.3M
- EGRX 50.7M
- IPO Year
- BCG N/A
- EGRX 2014
- Fundamental
- Price
- BCG $2.80
- EGRX $1.99
- Analyst Decision
- BCG
- EGRX
- Analyst Count
- BCG 0
- EGRX 0
- Target Price
- BCG N/A
- EGRX N/A
- AVG Volume (30 Days)
- BCG 12.9K
- EGRX 321.6K
- Earning Date
- BCG 08-15-2024
- EGRX 11-12-2024
- Dividend Yield
- BCG N/A
- EGRX N/A
- EPS Growth
- BCG N/A
- EGRX N/A
- EPS
- BCG N/A
- EGRX 0.91
- Revenue
- BCG $161,897,000.00
- EGRX $257,551,000.00
- Revenue This Year
- BCG N/A
- EGRX N/A
- Revenue Next Year
- BCG N/A
- EGRX N/A
- P/E Ratio
- BCG N/A
- EGRX $2.35
- Revenue Growth
- BCG N/A
- EGRX N/A
- 52 Week Low
- BCG $2.60
- EGRX $1.80
- 52 Week High
- BCG $16.61
- EGRX $14.78
- Technical
- Relative Strength Index (RSI)
- BCG N/A
- EGRX 19.60
- Support Level
- BCG N/A
- EGRX $1.80
- Resistance Level
- BCG N/A
- EGRX $4.11
- Average True Range (ATR)
- BCG 0.00
- EGRX 0.40
- MACD
- BCG 0.00
- EGRX -0.19
- Stochastic Oscillator
- BCG 0.00
- EGRX 6.86
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About EGRX Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.